USA:

Europe:

Email:

Consultation

C5a ELISA Kit

  • Product Information
  • Description
Catalog: C-EL-1720T
Product Type: Test kit
Size: 96 tests
Principle: Solid Phase Sandwich ELISA
Conjugation: HRP
Species: Human
Detection range: 39.06-2500 pg/mL
Sensitivity: 1.65 pg/mL
Specificity: Recognizes both recombinant and natural Human C5
Sample type: Serum
Test type: Quantitative
Analysis mode: ELISA
Shipping: This ELISA Kit is shipped at ambient temperature.
Storage: 2-8℃
Full name: complement component 5

This C5a ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human C5 protein in Serum . It contains recombinant Human C5, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a is quickly metabolised by carboxypeptidases, forming the less potent C5adesArg. Acting via a classical G protein-coupled receptor, CD88, C5a and C5adesArg exert a number of effects essential to the innate immune response, while their actions at the more recently discovered non-G protein-coupled receptor, C5L2 (or GPR77), remain unclear. The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis.

Verification Code
top